Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lilly Stays Committed To Alzheimer's, Including Amyloid Hypothesis, Despite Many Failures

14 Jun 2018

• By Mandy Jackson

Sand running through the bulbs of an hourglass measuring the passing time in a countdown to a deadline, on a dark background with copy space.

Related Content

Lilly ends Phase III development of gamma secretase inhibitor for Alzheimer's

17 Aug 2010

Eisai/Biogen Remain In BACE Race As Alzheimer's Contenders Dwindle

06 Jun 2018

Alzheimer's Disease: Learning the Lessons Of The Past To Prepare For The Future

08 Dec 2015

Lilly’s Solanezumab Fails, But The Surprise Would Have Been Success

23 Nov 2016

Another Nail In Amyloid Hypothesis Coffin? Merck Ends Pivotal BACE Inhibitor Study

15 Feb 2017

M&A Pressure Mounts For Merck & Co After Alzheimer's Drug Dismissed

14 Feb 2018

Lilly/AstraZeneca's Lanabecestat Becomes Latest BACE Inhibitor Casualty

12 Jun 2018

Related Companies

Eli Lilly and Company

AstraZeneca PLC

Merck & Co., Inc.

Eisai Co., Ltd.

Biogen, Inc.

Additional Topics

Business Strategies Companies Commercial Neurology BioPharmaceutical

More from Neurological

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.